Trinity Biotech PLC

TRIB Healthcare Medical Devices

Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024.

Revenue
+43.3%
EPS
+52.1%
Free cash flow
+75.2%
Total debt
+29.9%

Quarter to March 2026, against a year earlier

6.07 0.17 +2.88%
Market cap
$3.8M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
4/9
Altman Z
−2.78
Beneish M
−4.29
Dividend safety
n/a
Mar '26 Dec '25 Sep '25 Jun '25 Older periods
ROE
55.26% 69.76% 90.93% 92.42%

+8 more TTM periods

Piotroski F-Score
4 4 2 1
ROA
(32.70%) (35.86%) (36.64%) (37.61%)
ROIC
(12.61%) (16.99%) (23.73%) (25.55%)
Return on Tangible Assets
30.75% 37.37% (732.37%) (630.54%)
Average Days of Receivables
81.54 95.70 108.88 80.47
Free Cash Flow per Share
(6.78) (22.76) (18.00) (26.07)
Free Cash Flow
(4.28) (14.08) (11.18) (16.17)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026